Chinese biopharma firm Everest Medicines Ltd. will license an mRNA Covid-19 vaccine from Canada’s Providence Therapeutics Holdings Inc., as companies try to bring the most effective inoculation platform into China despite its apparent resistance to western shots.
Everest will gain rights to Providence’s vaccine in Greater China and countries including Indonesia, Singapore, and Thailand, it said in a statement Monday. It will pay $100 million cash upfront for access to the vaccines and mRNA technology, and up to $100 million in profit-sharing, the statement said. The deal includes another payment of up to $300 million in stock if further products are developed using Providence’s mRNA technology platform.
While almost 1 billion people have been fully vaccinated in China, the country is still lacking an mRNA shot, with most of the population inoculated with inactivated vaccines from Sinopharm Group Co. and Sinovac Biotech Ltd., which studies have found to be less effective. A deal by Fosun Pharmaceutical Group Co. to sell BioNTech SE’s mRNA shot in mainland China has yet to be approved by regulators, suggesting it may not be easy to bring in a foreign mRNA vaccine, partly because of political sensitivities.
If approved, the Everest-Providence vaccine will likely be used as a booster shot in China given most of the population has been vaccinated, Everest Chief Executive Officer Kerry Blanchard said in an interview. In other Asian nation’s within Everest’s remit, there’s still the need for primary vaccination, he said.
“That’s still a large group of people,” Blanchard said. “I think it’s a reasonable assumption that most adults will likely need a booster at some point, and the older you are, the more rapidly the immunity wanes. People will need to have at least one booster.”
